[Co-operative on salvage chemotherapy with VP-16 for malignant lymphoma. Hanshin Study Group on Treatment for Hematological Disorders]

E Miyazaki; Y Takemoto; A Kanamaru; E Kakishita; K Nagai; T Masaoka; H Shibata; A Horiuti; K Tsubaki; T Yonezawa

[Co-operative on salvage chemotherapy with VP-16 for malignant lymphoma. Hanshin Study Group on Treatment for Hematological Disorders]

Gan To Kagaku Ryoho. 1992 Apr;19(4):497-503.

[Article in Japanese]

Authors

E Miyazaki¹, Y Takemoto, A Kanamaru, E Kakishita, K Nagai, T Masaoka, H Shibata, A Horiuti, K Tsubaki, T Yonezawa, et al.

Affiliation

¹ Second Dept. of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.

PMID: 1558399

Abstract

Forty one patients with refractory malignant lymphoma were treated with a combination of VP-16, ACM, BH-AC, MTX and PDN as a salvage chemotherapy. These patients were either resistant to frontline therapy or refractory in their relapses. Three patients (7%) achieved a complete remission and 14 patients (34%) attained a partial remission. An overall response rate was 41%. Major toxicities were myelosuppression, nausea, and vomiting. However, they were well tolerated. This regimen has been effective in the treatment for the patients with refractory malignant lymphoma.

Publication types

Clinical Trial
English Abstract
Multicenter Study

MeSH terms

Aclarubicin / administration & dosage
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cytarabine / administration & dosage
Cytarabine / analogs & derivatives
Etoposide / administration & dosage*
Female
Hodgkin Disease / drug therapy
Humans
Immunoblastic Lymphadenopathy / drug therapy
Leukemia-Lymphoma, Adult T-Cell / drug therapy
Lymphoma, Non-Hodgkin / drug therapy*
Male
Methotrexate / administration & dosage
Middle Aged
Prednisolone / administration & dosage

Substances

Cytarabine
Etoposide
Aclarubicin
Prednisolone
enocitabine
Methotrexate